Abstract
The immunogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant severe acute respiratory syndrome (SARS) coronavirus lacking the E gene (rSARS-CoV-DeltaE) were studied using hamsters. Hamsters immunized with rSARS-CoV-DeltaE developed high serum-neutralizing antibody titers and were protected from replication of homologous (SARS-CoV Urbani) and heterologous (GD03) SARS-CoV in the upper and lower respiratory tract. rSARS-CoV-DeltaE-immunized hamsters remained active following wild-type virus challenge, while mock-immunized hamsters displayed decreased activity. Despite being attenuated in replication in the respiratory tract, rSARS-CoV-DeltaE is an immunogenic and efficacious vaccine in hamsters.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Viral / blood
-
Cricetinae
-
Gene Deletion
-
Lung / pathology
-
Lung / virology
-
Mesocricetus
-
Neutralization Tests
-
Respiratory System / virology
-
Severe Acute Respiratory Syndrome / immunology
-
Severe Acute Respiratory Syndrome / prevention & control*
-
Severe acute respiratory syndrome-related coronavirus / genetics
-
Severe acute respiratory syndrome-related coronavirus / immunology*
-
Vaccines, Attenuated
-
Viral Envelope Proteins / genetics
-
Viral Vaccines / genetics
-
Viral Vaccines / immunology*
-
Viroporin Proteins
Substances
-
Antibodies, Viral
-
E protein, SARS coronavirus
-
Vaccines, Attenuated
-
Viral Envelope Proteins
-
Viral Vaccines
-
Viroporin Proteins